The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS member or an individual non-member subscription to the journal. Background. Acute kidney injury (AKI) after cardiac surgery is associated with worse outcomes. However, it is not known how adverse long-term consequences vary according to the duration of AKI. We sought to determine the association between duration of AKI and survival.
A cute kidney injury (AKI) is common in hospitalized patients and is independently associated with an increased risk of morbidity, mortality, and length of stay [1] . Acute kidney injury occurs in 2% to 30% of patients undergoing cardiac surgery, depending on the definition [2] . Long-term survival in patients who undergo cardiac surgery is proportional to severity of AKI, at least as assessed by peak changes in serum creatinine (SCr) [3] . The dose-response relationship between severity of AKI and long-term survival has been demonstrated in several other settings as well [4] . Most recent epidemiologic studies of AKI have used the consensus definitions of Risk Injury Failure Loss End-stage (RIFLE) or the Acute Kidney Injury Network (AKIN) to classify severity of AKI [3] . These definitions assess the magnitude of SCr elevation as the primary dimension to grade severity (change from baseline to peak creatinine). The AKIN definition also incorporates tempo as a prerequisite (the increase must occur during a period of 48 hours), but both definitions ignore a potentially important third dimension of the severity of AKI: duration. Not only does duration of SCr elevation intuitively denote severity of AKI in the clinical arena, but the duration of SCr elevation has also been suggested as a better end point for trials of AKI [5] . However, the value of duration of AKI for predicting long-term survival has not been thoroughly studied.
Thus, we sought to determine the association between duration of SCr elevation and long-term survival in cardiac surgery patients. Cardiac surgery is an ideal setting in which to assess this relationship, as AKI is common in this setting, the timing of the insult is known, and SCr measurement is generally conducted on a daily basis for the first 2 postoperative days. Subsequent SCr measurements are done according to clinical indications until discharge.
Material and Methods
We prospectively enrolled 4,987 consecutive cardiac surgery patients from 2002 through 2007. Patients with a history of dialysis were excluded from the analysis (n ϭ 70). Eighty-five patients were excluded because they did not have valid procedure dates and thus AKI duration was not calculated. The Maine Medical Center Institutional Review Board has approved this study and waived the need for patient consent.
Duration and Staging of Acute Kidney Injury
The last preoperative SCr value before surgery was compared with each postoperative SCr as a measure of AKI. Serum creatinine was measured daily until 48 hours after surgery, followed by additional days of measurement per the attending provider's discretion. All SCr laboratory measures were conducted as part of the hospital's standing protocol, and no SCr measurements were conducted for research. Acute kidney injury was defined as at least a 0.3 (mg/dL) or at least a 50% increase in SCr from baseline for each postoperative day [6] . Duration of AKI was defined by the number of days AKI was present and categorized as no AKI and AKI for 1 to 2, 3 to 6, and at least 7 days. Severity of AKI was classified by AKIN staging criteria [6] . We also classified AKI into transient and persistent categories on the basis of renal recovery back to baseline at the time of discharge (SCr values returning to no AKI status).
Patient Follow-Up
Patients were followed up during the index hospital admission for cardiac surgery until discharge. Baseline, procedural, and clinical outcomes were collected at discharge. Long-term follow-up for mortality was obtained by linking the registry to the Social Security Death Master File (SSDMF) [7] . Patients were matched by name, social security number, and date of birth [8] . Follow-up time was calculated from the date of the procedure to the date of death recorded by the SSDMF, as previously described [9, 10] .
Statistical Analysis
Baseline patient and disease characteristics and clinical outcomes were summarized by percentage and mean (Ϯ standard deviation). We used 2 tests and tests of trend to assess similarities between categories of duration of AKI. Degrees of freedom for the 2 test depended on the number of groups. We used an alpha of 0.05. In Table 1 ) [11] . All other continuous variables were tested using Cuzick's nonparametric test for trend across ordered groups of duration of AKI, which is an extension of the Wilcoxon rank-sum test. All variables in Table 2 were tested using the 2 test, except for AKIN stages, percent changes in peak SCr, and length of stay, which were compared using test of trend.
Kaplan-Meier techniques were used to conduct the survival analysis and failure plots for time to AKI recovery; patients were stratified by the duration of AKI postoperatively. Cox's proportional hazard models were used to calculate crude and adjusted hazard ratios (HR) with no AKI as the referent, adjusting for age, sex, prior coronary artery bypass grafting, chronic obstructive pulmonary disease, emergency surgery, ejection fraction, and baseline estimated glomerular filtration rate as a result of biologic plausibility and univariate associations with survival and duration of AKI. Adjusted HRs were reported with 95% confidence intervals and probability values. Propensity-matched blocks were created using AKI categories, matching on covariates listed above, and Cox's proportional hazard modeling was conducted across the propensity-matched blocks. All analyses were conducted using Stata 11.0 (College Station, TX).
Results
During the study period, 39% (1,886 of 4,837 patients) of patients exhibited AKI. We stratified patients by duration of AKI: no AKI (2,951), 1 to 2 days of AKI (896; 18.5%), 3 to 6 days (552; 10.8%), and at least 7 days (438; 9.1%). Patients experiencing AKI significantly differed with regard to baseline patient and disease characteristics (Table 1), with lower baseline estimated glomerular filtration rate, longer duration on cardiopulmonary bypass, and other comorbidities representing important risk factors for the development and duration of AKI. We displayed the time to AKI recovery (duration of AKI) in Figure 1 ; nearly 50% of patients with AKI recovered after 2 days; however, the remaining AKI patients took as long as 3 months to recover renal function.
Clinical Outcomes
Acute Kidney Injury Network stage was associated with duration of AKI, where stage 2 and 3 AKIN patients experienced AKI for more days than AKIN stage 1 patients who experienced a more transient episode of AKI ( Table 2 ). The duration of AKI provided additional predictive information for 5-year mortality risk versus that of AKIN stage alone. In-hospital unfavorable outcomes were also more common among patients with a longer duration of AKI, except for a new onset of Q-wave myocardial infarction. Longer durations of AKI were more likely to result in acute dialysis (Table 2) .
Long-Term Mortality
The Kaplan-Meier survival plot demonstrates that patients with longer durations of AKI die more often during the 5 years after cardiac surgery than patients with shorter durations of AKI (p Ͻ 0.001; Fig 2) with an average follow-up of 2.6 years (median, 2.6 years). The proportion of patients, adjusted HR, and 95% confidence interval (CI) for AKI duration (no AKI as referent) are reported in Table 3 and are as follows: 1 to 2 days (18%; HR, 1.66; 95% CI, 1.32 to 2.09), 3 to 6 days (11%; HR, 1.94; 95% CI, 1.51 to 2.49), and at least 7 days (9%; HR, 3.40; 95% CI, 2.73 to 4.25). This graded relationship of duration of AKI with long-term mortality persisted when patients who died during hospitalization were excluded from analysis (Table 3) .
We further divided our AKI duration groups to compare transient AKI (AKI resolved by the time of discharge), persistent AKI (unresolved AKI at the time of discharge), and new onset of acute dialysis (Fig 3, Table  3 ). We discovered there was an immediate upfront mortality risk equal to that of acute dialysis among patients who were discharged with AKI unresolved. The adjusted HR for patients in this subgroup analysis confirmed these findings, with no AKI as the referent ( (Table 3 ).
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There are several limitations of this study. First, this is a prospectively collected, retrospectively analyzed singlecenter study. Second, we reported on long-term survival but we did not have information on long-term incidence of end-stage renal disease or mode of death. Third, we lacked postdischarge follow-up on kidney function in patients with persistent AKI. However, our study also has several strengths. This is a modern prospective cohort of consecutive patients with a broad mix of comorbidities, race, and sex, which permits adequate generalizability of our findings. Patients were followed up during a period when many evidenced-based processes, such as tight glucose control, conservative blood transfusion strategies, and low tidal volumes have become standard of care [20 -23] . Furthermore, SCr measurements were performed daily until 48 hours after surgery on all participants; after 48 hours, SCr measurements were ordered per provider discretion until hospital discharge.
Conclusions
Acute kidney injury, once thought to be benign when SCr returned to baseline, has significant long-term implications. Not only does AKI potentially drive the increased mortality, it is likely a surrogate for other end-organ injuries. The fact that the duration of AKI differentiates AKI from volume-responsive renal dysfunction and is proportional to the amount of renal injury and mortality compels us to have more impetus to change our processes of care, specifically with regard to AKI. The duration of AKI after cardiac surgery is directly proportional to long-term mortality. This AKI dosedependent effect on long-term mortality helps to close the gap between association and causation, whereby AKI and AKI duration have important implications for patient care and can aid clinicians in evaluating the risk of in-hospital and postdischarge death. Acute kidney injury duration can also be used as a surrogate outcome for long-term mortality in intervention trials to prevent or treat AKI. The long-term implications of AKI compel us to have some urgency regarding seeking changes of processes of care specifically regarding renal-protective strategies. 
